Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 6:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Teriflunomide HMR1726 Clear all
Completed Phase 3 Interventional Results available

Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis

NCT00134563
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for teriflunomide)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,088 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 26, 2026, 6:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis

NCT02201108
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
4
States / cities
Cullman, Alabama • Tampa, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 26, 2026, 6:05 PM EDT
Active, not recruiting Phase 4 Interventional

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

NCT03535298
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Early Highly Effective Therapies Group, Escalation Therapies Group
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 26, 2026, 6:05 PM EDT
Completed No phase listed Observational

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT02776072
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
2,978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
38
States / cities
Homewood, Alabama • Gilbert, Arizona • Hanford, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 26, 2026, 6:05 PM EDT
Completed Phase 2 Interventional Results available

Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study

NCT00273364
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Hematopoietic Stem Cell Therapy, Standard treatment with a conventional drug
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 26, 2026, 6:05 PM EDT
Completed Not applicable Interventional

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

NCT03500328
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 26, 2026, 6:05 PM EDT
Completed Phase 4 Interventional Results available

MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV

NCT01970410
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
teriflunomide
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
21 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
3
States / cities
Phoenix, Arizona • Latham, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 26, 2026, 6:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mechanistic Studies of Teriflunomide in RRMS

NCT03464448
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Teriflunomide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 26, 2022 · Synced Sep 26, 2026, 6:05 PM EDT
Terminated Phase 3 Interventional Results available

Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

NCT04338061
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Teriflunomide, Evobrutinib
Drug
Lead sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
38
States / cities
Cullman, Alabama • Scottsdale, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 26, 2026, 6:05 PM EDT
Completed Phase 3 Interventional Results available

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

NCT04410978
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Tolebrutinib, Teriflunomide, Placebo to match Tolebrutinib, Placebo to match Teriflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 26, 2026, 6:05 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride

NCT02263547
View directory record Official record
Conditions
Teriflunomide Elimination, Healthy Volunteers
Interventions
teriflunomide, Colestipol
Drug
Lead sponsor
Derrick Scott Robertson
Other
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 26, 2026, 6:05 PM EDT
Completed Phase 2 Interventional Results available

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

NCT00811395
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for teriflunomide), Interferon-β [IFN-β], Glatiramer Acetate [GA]
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 30, 2012 · Synced Sep 26, 2026, 6:05 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

NCT00489489
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for Teriflunomide), Interferon-β
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Sep 26, 2026, 6:05 PM EDT
Completed Phase 3 Interventional Results available

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

NCT04410991
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Tolebrutinib, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
43
States / cities
Cullman, Alabama • Phoenix, Arizona • Arcadia, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 26, 2026, 6:05 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

NCT00475865
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for teriflunomide), Glatiramer Acetate (GA)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Sep 26, 2026, 6:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

An Observational Study on Teriflunomide-exposed Pregnancies

NCT03198351
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide (HMR1726)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 26, 2026, 6:05 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions
Tolebrutinib, Placebo, Teriflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
52
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 26, 2026, 6:05 PM EDT
Completed No phase listed Observational

Teriflunomide Tecfidera LMCE

NCT03526224
View directory record Official record
Conditions
Tecfidera, Teriflunomide
Interventions
Dimethyl Fumarate, Teriflunomide
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 26, 2026, 6:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months

NCT01881191
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
MRI
Other
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Sep 26, 2026, 6:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis

NCT02651545
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Sep 26, 2026, 6:05 PM EDT
Completed Phase 4 Interventional Results available

Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients

NCT01895335
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
75
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Sep 26, 2026, 6:05 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

NCT00622700
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
19
States / cities
Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 26, 2026, 6:05 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

NCT06141473
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Frexalimab, Teriflunomide, Placebo infusion, Placebo tablet, MRI contrast-enhancing agents, Cholestyramine, Activated charcoal
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
99
States / cities
Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 84 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 26, 2026, 6:05 PM EDT
Terminated Phase 3 Interventional Results available

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

NCT04338022
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Teriflunomide, Evobrutinib
Drug
Lead sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
51
States / cities
Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 26, 2026, 6:05 PM EDT